FATP2/SLC27A2 Antibody (466106) [PerCP]
Novus Biologicals, part of Bio-Techne | Catalog # FAB4659C
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
CyTOF-ready, Intracellular Staining by Flow Cytometry
Label
PerCP (Excitation = 490 nm, Emission = 675 nm)
Antibody Source
Recombinant Monoclonal Mouse IgG1 Clone # 466106
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
HEK293 human embryonic kidney cell line transfected with human FATP2
Met1-Leu620
Accession # O14975
Met1-Leu620
Accession # O14975
Specificity
Detects human FATP2. Stains human FATP2 transfectants but not irrelevant transfectants.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for FATP2/SLC27A2 Antibody (466106) [PerCP]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Intracellular Staining by Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: FATP2
Long Name
Fatty Acid Transport Protein 2
Alternate Names
ACSVL1, FACVL1, SLC27A2, THCA-CoA ligase, VLACS, VLCS
Gene Symbol
SLC27A2
Additional FATP2 Products
Product Documents for FATP2/SLC27A2 Antibody (466106) [PerCP]
Product Specific Notices for FATP2/SLC27A2 Antibody (466106) [PerCP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...